Unaudited financial results - June 30, 2025
FERMENTA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Fermenta Biotech's Board approved unaudited Q1 FY26 results on August 12, 2025. Standalone revenue from operations dipped slightly to ₹11,901.87 lakhs vs ₹12,203.79 lakhs YoY, while total income rose modestly to ₹12,785.95 lakhs aided by higher other income (₹884.08 lakhs vs ₹388.30 lakhs). Standalone profit after tax fell sharply to ₹1,623.38 lakhs from ₹2,931.12 lakhs YoY, with EPS at ₹5.57 vs ₹10.05. Consolidated revenue declined to ₹13,626.27 lakhs and PAT dropped to ₹2,160.17 lakhs (₹7.49 EPS) from ₹3,332.34 lakhs. The profit decline was driven mainly by sharply lower property segment income (₹355.22 lakhs vs ₹1,089.57 lakhs YoY). Auditors SRBC & Co LLP issued an unqualified limited review report.
Weak operating show with sharp YoY profit fall despite stable revenues points to margin compression. Bulk drugs segment held up but property divestment timing hurt profitability this quarter, which the stock may view negatively.